Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology

European Respiratory Journal

Volumn 39, Issue 5, 2012, Pages 1144-1155

  Bello, Salvador ^a   Lasierra, Ana B ^a   Mincholé, Elisa ^a   Fandos, Sergio ^a   Ruiz, Maria Angeles ^a   Vera, Elisabeth ^a   De Pablo, Francisco ^a   Ferrer, Miguel ^b   Menendez, Rosario ^c   Torres, Antoni ^b  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Aetiology; Biomarkers; Community acquired pneumonia; Midregional proadrenomedullin; Outcome

Indexed keywords

C REACTIVE PROTEIN; METICILLIN; PROADRENOMEDULLIN; PROCALCITONIN; UREA;

ACCURACY; ACHROMOBACTER DENITRIFICANS; ACHROMOBACTER XYLOSOXIDANS; ADENOVIRUS; ADULT; AGE; AGED; ARTICLE; BACTERIAL PNEUMONIA; BLOOD ANALYSIS; BREATHING RATE; CHLAMYDOPHILA PNEUMONIAE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONFUSION; CORONAVIRUS; CORRELATION ANALYSIS; CORYNEBACTERIUM STRIATUM; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FEMALE; FOLLOW UP; HAEMOPHILUS INFLUENZAE; HUMAN; HUMAN METAPNEUMOVIRUS; IMMUNOCOMPETENCE; INFLUENZA VIRUS A; INFLUENZA VIRUS B; LEGIONELLA PNEUMOPHILA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; MORAXELLA CATARRHALIS; MORTALITY; MYCOPLASMA PNEUMONIAE; PNEUMONIA SEVERITY INDEX; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RHINOVIRUS; SERRATIA MARCESCENS; SPUTUM ANALYSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS HOMINIS; STREPTOCOCCUS PNEUMONIAE; SYSTOLIC BLOOD PRESSURE; UREA BLOOD LEVEL; VIRUS PNEUMONIA;

ADRENOMEDULLIN; AGED; BIOLOGICAL MARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CALCITONIN; COMMUNITY-ACQUIRED INFECTIONS; CONFUSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PNEUMONIA, BACTERIAL; PNEUMONIA, VIRAL; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; RESPIRATORY RATE; SEVERITY OF ILLNESS INDEX; SMOKING; UREA;

EID: 84859207085     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00080411     Document Type: Article

References (27)

1. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250. (Pubitemid 27044625)
2. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377-382. (Pubitemid 36560938)
3. Capelastegui A, España PP, Quintana JM, et al. Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J 2006; 27: 151-157. (Pubitemid 43092679)
4. Mortensen EM, Kapoor WN, Chang CC, et al. Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia. Clin Infect Dis 2003; 37: 1617-1624. (Pubitemid 37549947)
5. Johnstone J, Eurich DT, Majumdar SR, et al. Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: a population-based cohort study. Medicine (Baltimore) 2008; 87: 329-334.
6. Niederman MS. Biological markers to determine eligibility in trials for community-acquired pneumonia: a focus on procalcitonin. Clin Infect Dis 2008; 47: Suppl. 3, S127-S132.
7. Krüger S, Ewig S, Papassotiriou J, et al. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP - results from the German competence network CAPNETZ. Respir Res 2009; 10: 65.
8. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174: 84-93. (Pubitemid 43955248)
9. Menéndez R, Martínez R, Reyes S, et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 2009; 64: 587-591.
10. Krüger S, Ewig S, Marre R, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Resp J 2008; 31: 349-355.
11. Christ-Crain M, Morgenthaler NG, Stolz D, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia. [ISRCTNO4176397]. Crit Care 2006; 10: R96.
12. Krüger S, Ewig S, Giersdorf S, et al. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia. Results from the German competence network CAPNETZ. Am J Respir Crit Care Med 2010; 182: 1426-1434.
13. Schuetz P, Wolbers M, Christ-Crain M, et al. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care 2010; 14: R106.
14. Huang DT, Angus DC, Kellum JA, et al. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest 2009; 136: 823-831.
15. Guertler C, Wirz B, Christ-Crain M, et al. Inflammatory response predict long-term mortality risk in community-acquired pneumonia. Eur Respir J 2011; 37: 1439-1446.
16. Haeuptle J, Zaborsky, Fiumefreddo R., et al. Prognostic value of procalcitonin in Legionella pneumonia. Eur J Clin Microbiol Infect Dis 2009; 28: 55-60.
17. Alfageme I, Aspa J, Bello S, et al. Normativas para el diagnostico y el tratamiento de la neumonía adquirida en la comunidad. Sociedad Española de Neumología y Cirugía Torácica (SEPAR) [Guidelines for the diagnosis and management of communityacquired pneumonia. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR)]. Arch Bronconeumol 2005; 41: 272-289.
18. Morgenthaler NG, Struck J, Alonso C, et al. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005; 51: 1823-1829. (Pubitemid 41368172)
19. Coiras MT, Aguilar JC, Garcia ML, et al. Simultaneous detection of fourteen respiratory viruses in clinical specimens by two multiplex reverse transcription nested-PCR assays. JMed Virol 2004; 72: 484-495. (Pubitemid 38133991)
20. Sample and Assay Technologies. ResPlex II handbook. Hamburg, Qiagen, 2010.
21. Christ-Crain M, Morgenthaler NG, Struck J, et al. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care 2005; 9: R816-R824.
22. Guignant C, Voirin N, Venet F, et al. Assessment of pro-vasopressin and pro-adrenomedullin as predictors of 28-day mortality in septic shock patients. Intensive Care Med 2009; 35: 1859-1867.
23. Albrich WC, Dusemund F, Ruegger K, et al. Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm. BMC Infect Dis 2011; 11: 112.
24. Mortensen EM, Coley CM, Singer DE, et al. Causes of death for patients with community-acquired pneumonia. Results from thePneumonia Patient Outcomes Research Team Cohort Study. Arch Intern Med 2002; 162: 1059-1064. (Pubitemid 34492537)
25. Yende S, D'Angelo G, Kellum JA, et al. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 2008; 177: 1242-1247.
26. Ruuskanen O, Lathi E, Jennings LC, et al. Viral pneumonia. Lancet 2011; 377: 1264-1275.
27. Ewig S, Torres A. Community-acquired pneumonia as an emergency: time for an aggressive intervention to lower mortality. Eur Respir J 2011; 38: 253-260.